Infermedica raises $10.25 million in Series A funding

Infermedica, the Poland-based artificial intelligence (AI) health tech startup, has scored $10.25 million in Series A funding it’ll use for platform R&D.

The funding round was led by the European Bank for Reconstruction and Development and digital health fund Heal Capital, with participation from existing investors Karma Ventures, Inovo Venture Partners, and Dreamit Ventures.

This round brings total funding to date to $15 million.

Infermedica says it’ll use the investment on platform R&D to enhance patient triage and symptom checking features, and clinical decision support analysis. The company also plans to expand its operations in Germany and the U.S.

Founded in 2012 by CEO Piotr Orzechowski, Infermedica’s AI-driven and multi-language platform aids patient care and the digital delivery of health care services. Combining the expertise of doctors with the company’s AI and machine learning algorithms, Infermedica delivers rapid symptom triage and instructions so patients can receive health care services quickly.

The tech startup operates on a B2B model and works with insurance providers, telemedicine companies and health care organizations to provide patients with digitally delivered symptom checks. To date, Infermedica’s solutions have been used over 6 million times.

The platform currently includes three solutions: a customizable symptom checker that provides digital symptom checking and analysis; call centre triage that enables telemedicine personnel to pre-diagnose patients and understand the severity of their condition; and Infermedica API, which enables organizations to integrate Infermedica’s medical diagnosis API into their website, app or telehealth system.

“Our mission is to improve quality and access to primary care with the use of AI-powered, constantly improving technology,” said Orzechowski.

“As we all know, the COVID-19 pandemic has placed great pressure on health systems globally and it’s our obligation to help healthcare providers deliver safe and timely care. This additional funding will enable us to continue developing cutting-edge AI-triage technology and expand our commercial operations in the US and Germany,” he added.

Heal Capital managing partner Dr. Christian Weiss commented, “Technology has the capability to transform healthcare, but there needs to be real harmony between innovation and human expertise – Infermedica has found it. The platform is streamlining healthcare delivery for doctors and patients, and its continuous high accuracy, alongside the company’s dedication to innovative technology is very impressive.”

Infermedica has nearly 60 B2B clients in the health care space. Notable partners and clients include Allianz, Global Excel, Sana Kliniken, Médis and Microsoft, which uses the Infermedica platform within its health care bot.